1: Eye (Lond). 2010 Mar 12; [Epub ahead of print] 

Use of pegaptanib for recurrent and non-clearing vitreous haemorrhage in
proliferative diabetic retinopathy.

Hornan D, Edmeades N, Krishnan R, Khan J, Lochhead J.

Ophthalmology Department, St Mary's Hospital, Isle of Wight, Newport, Hants, UK.

PurposeDiabetes is the leading cause of blindness in the United Kingdom among
people of working age. Many with proliferative diabetic retinopathy (PDR) go on
to develop vitreous haemorrhage (VH). Those with recurrent or non-clearing VH
require vitrectomy to restore vision. Pegaptanib is a vascular endothelial
growth factor antagonist that disrupts the proliferative cascade and has been
shown to precipitate regression of retinal neovascularisation. We assessed the
effect of pre-operative intravitreal (IVT) pegaptanib on the timing, difficulty,
and outcome of vitrectomy for recurrent VH in PDR.MethodsFourteen consecutive
patients (15 eyes) were given a course of 1-3 IVT pegaptanib injections and
vitrectomy was performed when indicated by the recurrence or persistence of VH,
or progression of associated tractional retinal detachment (TRD).ResultsThe
range of patient follow-up was from 6 months to 2 years. All had no further VH
for at least 4 weeks after IVT pegaptanib. Five eyes remained free from VH until
the end of the study (8-25 months), thus obviating the need for vitrectomy. Two
further cases avoided vitrectomy following further IVT pegaptanib. In the
majority of patients with VH, IVT pegaptanib created a window for further laser
and risk factor optimisation. Surgery was faster and less challenging, compared
with conventional vitrectomy for recurrent VH due to PDR.ConclusionsIVT
pegaptanib can be considered in diabetic patients with VH. Approximately
one-third may avoid vitrectomy altogether. There are clear intra-operative
advantages of using IVT pegaptanib pre-operatively. However, caution should be
exercised where there is pre-existing TRD.Eye advance online publication, 12
March 2010; doi:10.1038/eye.2010.14.

PMID: 20224599  [PubMed - as supplied by publisher]

2: Eye (Lond). 2010 Mar 5; [Epub ahead of print] 

Retinal vasculitis as an early sign of bacterial post-operative endophthalmitis.

Subbiah S, McAvoy CE, Best JL.

Royal Victoria Hospital, Belfast, County Antrim, UK.

PMID: 20203699  [PubMed - as supplied by publisher]

3: Eye (Lond). 2010 Feb 26; [Epub ahead of print] 

The Peterborough scheme for community specialist optometrists in glaucoma: a
feasibility study.

Syam P, Rughani K, Vardy SJ, Rimmer T, Fitt A, Husain T, McInerney L, Broome D,
Driver R, Wormald R, Ramirez-Florez S.

Eye Department, Peterborough & Stamford NHS Foundation Trust, Peterborough, UK.

PurposeThis study assessed the role of specialist optometrists who were working
in the community and sharing the care for glaucoma patients with, and under
close supervision of, a consultant ophthalmologist working in the Hospital Eye
Services (HES) to ensure high-quality standards, safety, and care.MethodsFrom
February 2005 onwards, the majority of all new glaucoma referrals to our eye
department were diverted to our specialist optometrists in glaucoma (SOGs) in
their own community practices. Selected patients in the HES setting who were
already diagnosed with stable glaucoma were also transferred to the SOGs. The
completed clinical finding details of the SOGs, including fundus photographs and
Humphrey visual field tests, were scrutinised by the project lead.ResultsThis
study included 1184 new patients seen by specialist optometrists between
February 2005 and March 2007. A total of 32% of patients were referred on to the
hospital, leaving the remaining 68% patients to be seen for at least their next
consultation in the community by the SOGs. The following levels of disagreement
were observed between SOGs and the project lead: on cup:disc ratio (11%), visual
field interpretation (7%), diagnosis (12%), treatment plan (10%), and outcome
(follow-up interval and location) (17%).ConclusionThis study indicates that
there is potential for a significant increase in the role of primary care
optometry in glaucoma management. The study also confirms a need for a
significant element of supervision and advice from a glaucoma specialist. The
important issue of cost effectiveness is yet to be confirmed.Eye advance online
publication, 26 February 2010; doi:10.1038/eye.2009.327.

PMID: 20186167  [PubMed - as supplied by publisher]

4: Eye (Lond). 2010 Feb 26; [Epub ahead of print] 

Juvenile xanthogranuloma: an unusual eyelid presentation.

Lim LT, McLaughlin S, Lavy T, Penman D, Dutton GN.

Eye Department, Royal Hospital for Sick Children, Glasgow, UK.

PMID: 20186166  [PubMed - as supplied by publisher]

5: Eye (Lond). 2010 Feb 26; [Epub ahead of print] 

Tattoo-associated uveitis.

Saliba N, Owen ME, Beare N.

St Paul's Eye Unit, Royal Liverpool University Hospital, Liverpool, UK.

PMID: 20186165  [PubMed - as supplied by publisher]

6: Eye (Lond). 2010 Feb 19; [Epub ahead of print] 

Re: The report 'irrigation of the capsular bag using a sealed-capsule irrigation
device and 5-fluorouracil' by Milverton.

Spalton DJ.

Department of Ophthalmology, St Thomas' Hospital, Ground Floor South Wing,
London, UK.

PMID: 20168349  [PubMed - as supplied by publisher]

7: Eye (Lond). 2010 Feb 19; [Epub ahead of print] 

Reply to Mr Spalton.

Milverton EJ.

Intraocular Implant Unit, Sydney Eye Hospital, Sydney New South Wales,
Australia.

PMID: 20168348  [PubMed - as supplied by publisher]

8: Eye (Lond). 2010 Feb 19; [Epub ahead of print] 

Spontaneous dislocation of an Artisan phakic IOL causing corneal decompensation
requiring an endothelial graft.

Harsum S, Tossounis C, Tappin MJ.

St Peters Hospital, Chertsey, England, UK.

PMID: 20168347  [PubMed - as supplied by publisher]

9: Eye (Lond). 2010 Feb 19; [Epub ahead of print] 

Changes in intraocular pressure and anterior segment morphometry after
uneventful phacoemulsification cataract surgery.

Dooley I, Charalampidou S, Malik A, Loughman J, Molloy L, Beatty S.

[1] Department of Ophthalmology, Waterford Regional Hospital, Waterford, Ireland
[2] Institute of Eye Surgery, Whitfield Clinic, Butlerstown North, Waterford,
Ireland.

PurposeTo study changes in anterior segment morphometry after uneventful
phacoemulsification cataract surgery, and to investigate whether there is a
relationship between any observed changes and intraocular pressure (IOP)
reduction after the procedure.MethodsThe anterior chamber depth (ACD), anterior
chamber volume (ACV), anterior chamber angle (ACA), central corneal thickness
(CCT), and IOP were measured in 101 non-glaucomatous eyes before and after
uneventful phacoemulsification cataract surgery.ResultsAfter cataract surgery,
the mean ACD, ACV, and ACA values increased by 1.08 mm, 54.4 mm(3), and 13.1
degrees , respectively, and the mean IOP (corrected for CCT) decreased by 3.2 mm
Hg. The predictive value of a previously described index (preoperative
ACD/preoperative IOP (corrected for CCT) or CPD ratio) for IOP (corrected for
CCT) reduction after cataract surgery was confirmed, reflected in an r(2) value
of 23.3% between these two parameters (P<0.001). Other indices predictive of IOP
reduction after cataract surgery were also identified, including preoperative
IOP/preoperative ACV and preoperative IOP/preoperative ACA, reflected in r(2)
values of 13.7 and 13.7%, respectively (P<0.001 and P<0.001,
respectively).ConclusionsOur study confirms the predictive value of the CPD
ratio for IOP reduction after cataract surgery, and may contribute to the
decision-making process in patients with glaucoma or ocular hypertension.
Furthermore, two novel indices of preoperative parameters that are predictive
for IOP reduction after cataract surgery were identified, and enhance our
understanding of the mechanisms underlying IOP changes after this procedure.Eye
advance online publication, 19 February 2010; doi:10.1038/eye.2009.339.

PMID: 20168346  [PubMed - as supplied by publisher]

10: Eye (Lond). 2010 Feb 12; [Epub ahead of print] 

Ranibizumab for retinal angiomatous proliferation in age-related macular
degeneration.

Atmani K, Voigt M, Le Tien V, Querques G, Coscas G, Soubrane G, Souied EH.

Department of Ophthalmology, Centre Hospitalier Intercommunal de Creteil,
University of Paris XII, Creteil, France.

PurposeTo assess the 1-year functional outcome and to evaluate the morphological
changes after intravitreal injections of ranibizumab in eyes affected with
retinal angiomatous proliferation (RAP) due to age-related macular degeneration
(AMD).MethodsA prospective, non-randomized, interventional study was conducted
on 26 consecutive patients with newly diagnosed RAP. All eyes were treatment
naive and were randomized to receive intravitreal injections of ranibizumab for
a 12-month period. After the first three monthly injections, re-treatment was
performed in case of best-corrected visual acuity (BCVA) loss of at least five
letters associated with fluid within the macula, central macular thickness (CMT)
increase of at least 100 mum, and/or persistence of fluid within the macula as
evaluated by optical coherence tomography, new onset macular haemorrhages,
persistence of leakage from the lesions on fluorescein angiography.ResultsAll
patients completed the 12-month follow-up: 25 of the 29 treated eyes (86.2%)
were stabilized, with a loss of less than 15 letters. Nineteen eyes (65.5%)
maintained or improved their BCVA, and three eyes (10.3%) gained three lines or
more. Overall, mean BCVA remained stable at the 12-month follow-up (-0.07
letters; P>0.05). Mean CMT significantly decreased from 386+/-147 to 216+/-74
mum at the 12-month follow-up. No significant adverse events were observed
during the study. The mean number of injections was 5.8+/-1.7 during the
follow-up period.ConclusionThe 1-year follow-up outcomes in our series suggest
that ranibizumab is an effective treatment for RAP in AMD, allowing
stabilization of BCVA and reduction of CMT.Eye advance online publication, 12
February 2010; doi:10.1038/eye.2010.9.

PMID: 20150927  [PubMed - as supplied by publisher]

11: Eye (Lond). 2010 Feb 12; [Epub ahead of print] 

Glued posterior chamber IOL in eyes with deficient capsular support: a
retrospective analysis of 1-year post-operative outcomes.

Kumar DA, Agarwal A, Prakash G, Jacob S, Saravanan Y, Agarwal A.

Dr Agarwal's Eye Hospital and Eye Research Centre, Chennai, India.

PurposeTo evaluate the post-operative outcome of fibrin glue-assisted posterior
chamber intraocular lens (IOL) implantation in eyes with deficient capsular
support after 1 year.MethodsEyes operated with fibrin glue-assisted posterior
chamber IOL implantation from December 2007 to May 2008 were included. The
post-operative best spectacle-corrected visual acuity (BCVA), uncorrected visual
acuity (UCVA), intraocular pressure (IOP), central macular thickness, and
specular count were evaluated. IOL position and centration at 1 year was
determined. The 1-year post-operative complications were analysed.ResultsA total
of 53 eyes of 53 patients were analysed. There was significant improvement in
UCVA (P=0.000) and BCVA (P=0.000). There was no significant change (P=0.447) in
IOP from the pre-operative value. The early post-operative complication was
decentration (5.6%). The late complication was pigment dispersion (3.7%) and
healed macular oedema (7.5%). No vision threatening complications such as
retinal break, retinal detachment, or endophthalmitis were seen. The percentage
(%) loss of endothelial cells was 5.23+/-3.4% at 1-year follow-up. No
pseudophakodonesis was seen in the follow-up visits.ConclusionResults obtained
at 1 year after fibrin glue-assisted posterior chamber IOL implantation showed a
good visual outcome with minimal complications in eyes with deficient capsular
support.Eye advance online publication, 12 February 2010;
doi:10.1038/eye.2010.10.

PMID: 20150926  [PubMed - as supplied by publisher]

12: Eye (Lond). 2010 Feb 12; [Epub ahead of print] 

Tear proteomics in evaporative dry eye disease.

Versura P, Nanni P, Bavelloni A, Blalock WL, Piazzi M, Roda A, Campos EC.

Ophthalmology Unit, University of Bologna, Bologna, Italy.

Purpose:To analyze tear protein variations in patients suffering from dry eye
symptoms in the presence of tear film instability but without epithelial
defects.Methods:Five microlitres of non-stimulated tears from 60 patients,
suffering from evaporative dry eye (EDE) with a break-up time (BUT) <10 s, and
from 30 healthy subjects as control (no symptoms, BUT >10 s) were collected.
Tear proteins were separated by mono and bi-dimensional SDS-PAGE electrophoresis
and characterized by immunoblotting and enzymatic digestion. Digested peptides
were analyzed by liquid chromatography coupled to electrospray ionization
quadrupole-time of flight mass spectrometry followed by comparative data
analysis into Swiss-Prot human protein database using Mascot. Statistical
analysis were performed by applying a t-test for independent data and a
Mann-Whitney test for unpaired data (P<0.05).Results:In EDE patients vscontrols,
a significant decrease in levels of lactoferrin (data in %+/-SD): 20.15+/-2.64
vs24.56+/-3.46 (P=0.001), lipocalin-1: 14.98+/-2.70 vs17.73+/-2.96 (P=0.0001),
and lipophilin A-C: 2.89+/-1.06 vs3.63+/-1.37 (P=0.006) was revealed, while a
significant increase was observed for serum albumin: 9.45+/-1.87 vs3.46+/-1.87
(P=0.0001). No changes for lysozyme and zinc alpha-2 glycoprotein (P=0.07 and
0.7, respectively) were shown. Proteomic analysis showed a downregulation of
lipophilin A and C and lipocalin-1 in patients, which is suggested to be
associated with post-translational modifications.Conclusions:Data show that tear
protein changes anticipate the onset of more extensive clinical signs in early
stage dry eye disease.Eye advance online publication, 12 February 2010;
doi:10.1038/eye.2010.7.

PMID: 20150925  [PubMed - as supplied by publisher]

13: Eye (Lond). 2010 Feb 12; [Epub ahead of print] 

The natural history of the Charles Bonnet Syndrome. Do the hallucinations go
away?

Jackson ML, Bassett KL.

Massachusetts Eye and Ear Infirmary, Harvard Department of Ophthalmology,
Boston, MA, USA.

PMID: 20150924  [PubMed - as supplied by publisher]

14: Eye (Lond). 2010 Feb 12; [Epub ahead of print] 

Comparison of three methods of intraocular pressure measurement and their
relation to central corneal thickness.

Carbonaro F, Andrew T, Mackey DA, Spector TD, Hammond CJ.

Twin Research and Genetic Epidemiology Unit, King's College London School of
Medicine, London, UK.

PurposeThe purpose of this study was to compare the reliability of the 'gold
standard' Goldmann applanation tonometer (GAT), with that of the ocular response
analyser (ORA), and the dynamic contour tonometer (DCT).Patients and methodsA
total of 694 subjects were recruited to participate from the TwinsUK (UK Adult
Twin Registry) at St Thomas' Hospital, London. Intraocular pressure (IOP) was
measured using GAT, ORA, and the DCT. The agreement between the three methods
was assessed using the Bland-Altman method. Repeatability coefficients and
coefficient of variation between first and second readings of the same eye were
used to assess reliability.ResultsMean age was 57.5 years (SD, 13.1; range,
16.1-88.5). The mean IOPs, calculated using the mean of two readings from the
right eye were as follows: Goldmann (GAT), 14.1+/-2.8 mm Hg; IOPg (ORA),
15.9+/-3.2 mm Hg; IOPcc (ORA), 16.6+/-3.2 mm Hg; and DCT, 16.9+/-2.7 mm Hg. The
95% limits of agreement were for ORA (IOPcc): GAT, -2.07 to 7.18 mm Hg; for DCT:
GAT, -0.49 to 6.21 mm Hg; and for DCT: ORA (IOPcc), -3.01 to 4.85 mm Hg.
Coefficients of variation for the three tonometers were GAT, 8.3%; ORA, 8.2%;
DCT, 6.3%. The repeatability coefficients were 3.4 mm Hg for GAT, 3.57 mm Hg for
ORA and 3.09 mm Hg for DCT. GAT and ORA (IOPg) readings showed a positive
correlation with central corneal thickness (P<0.005).ConclusionsThis study found
similar reliability in all three tonometers. Bland-Altman plots showed the three
instruments to have 95% limits of agreement outside the generally accepted
limits, which means they are not interchangeable. GAT measurements were found to
be significantly lower than the two newer instruments.Eye advance online
publication, 12 February 2010; doi:10.1038/eye.2010.11.

PMID: 20150923  [PubMed - as supplied by publisher]

15: Eye (Lond). 2010 Feb 12; [Epub ahead of print] 

Circulating markers of arterial thrombosis and late-stage age-related macular
degeneration: a case-control study.

Rudnicka AR, Maccallum PK, Whitelocke R, Meade TW.

Division of Community Health Sciences, St George's, University of London,
Cranmer Terrace, London, UK.

PurposeThe aim of this study was to examine the relation of late-stage
age-related macular degeneration (AMD) with markers of systemic
atherothrombosis.MethodsA hospital-based case-control study of AMD was
undertaken in London, UK. Cases of AMD (n=81) and controls (n=77) were group
matched for age and sex. Standard protocols were used for colour fundus
photography and to classify AMD; physical examination included height, weight,
history of or treatment for vascular-related diseases and smoking status. Blood
samples were taken for measurement of fibrinogen, factor VIIc (FVIIc), factor
VIIIc, prothrombin fragment F1.2 (F1.2), tissue plasminogen activator, and von
Willebrand factor. Odds ratios from logistic regression analyses of each
atherothrombotic marker with AMD were adjusted for age, sex, and established
cardiovascular disease risk factors, including smoking, blood pressure, body
mass index, and total cholesterol.ResultsAfter adjustment FVIIc and possibly
F1.2 were inversely associated with the risk of AMD; per 1 standard deviation
increase in these markers the odds ratio were, respectively, 0.62 (95%
confidence interval 0.40, 0.95) and 0.71 (0.46, 1.09). None of the other
atherothrombotic risk factors appeared to be related to AMD status. There was
weak evidence that aspirin is associated with a lower risk of
AMD.ConclusionsThis study does not provide strong evidence of associations
between AMD and systematic markers of arterial thrombosis, but the potential
effects of FVIIc, and F1.2 are worthy of further investigation.Eye advance
online publication, 12 February 2010; doi:10.1038/eye.2010.8.

PMID: 20150922  [PubMed - as supplied by publisher]

16: Eye (Lond). 2010 Feb 12; [Epub ahead of print] 

Use of heavy Trypan blue in macular hole surgery.

Lesnik Oberstein SY, de Smet MD.

Department of Ophthalmology, Academic Medical Center, University of Amsterdam,
Amsterdam, The Netherlands.

Purpose:Intraocular dyes facilitate the identification of the inner limiting
membrane (ILM) during surgery. Appropriate dyes should be safe, provide adequate
staining, and be easy to use. Heavy Trypan blue eliminates the need for an
air-fluid exchange (AFX) and appears to have little retinal toxicity. This study
refers to a prospective, consecutive trial with heavy Trypan blue in macular
hole surgery.Patients and methods:A consecutive group of 20 patients with full
thickness macular holes was recruited in a single institution study. Patients
were operated using conventional methods. Heavy Trypan blue was prepared by
mixing isovolumetrically glucose 10% with MembraneBlue (DORC, Zuidland, The
Netherlands). Patients were assessed for ease of surgery and post-operatively at
3 and 6 months (vision and ocular coherence tomography) for hole closure and
vision.Results:Twenty eyes were included in the study. Reapplication of dye was
used in 75% of the cases, leading to improved contrast further facilitating the
ILM peel. In no case was an AFX necessary to obtain sufficient staining. Macular
hole closure was achieved in 19 of 20 patients with one surgery. No retinal
detachment or other complication was observed in the follow-up
period.Conclusion:Heavy Trypan blue can be delivered efficiently to the retinal
surface without the need for an AFX. Staining was sufficient to help visualise
and peel the ILM. Repeat applications were easily performed. The macular hole
closure rate was similar to that of other series with a comparable visual
improvement.Eye advance online publication, 12 February 2010;
doi:10.1038/eye.2010.3.

PMID: 20150921  [PubMed - as supplied by publisher]